Company news

Indaptus Therapeutics, Inc. news in 2024

Indaptus Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

November 21, 2024

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 11, 2024

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

November 6, 2024

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

October 21, 2024

Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

October 14, 2024

Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses

September 4, 2024

Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 11, 2024

Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement

August 6, 2024

Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20

June 2, 2024

Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting

May 28, 2024

Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors

May 21, 2024

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

April 10, 2024

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

March 12, 2024

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

March 3, 2024

Decks in 2024